Outpatient treatment for portal hypertension
门静脉高压症的门诊治疗
基本信息
- 批准号:7801161
- 负责人:
- 金额:$ 22.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-03-01 至 2011-03-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdrenergic beta-AntagonistsAdverse eventAlcoholismAmericanAnimal ModelArea Under CurveBindingBlood PressureBlood flowCaringCirrhosisCleaved cellClinicalCollaborationsComplexDevelopmentDissociationDoseDrug Delivery SystemsDrug FormulationsEmergency SituationEmergency treatmentEmployeeEndopeptidasesEquilibriumEsophageal VarixEuropeEvaluationFrightFundingGeneral HospitalsGoalsHalf-LifeHemorrhageHepaticHepatitis BHepatorenal SyndromeHumanIn VitroInjection of therapeutic agentIntravenous BolusInvestigational DrugsLicensingLifeLiver CirrhosisLiver diseasesLysineMarketingMassachusettsMetal Binding SiteMetalsMonitorMusNanotechnologyNew AgentsNew Drug ApprovalsOperative Surgical ProceduresOrphanOutpatientsPatientsPeptide HydrolasesPeptidesPharmaceutical PreparationsPharmacological TreatmentPhasePhysiciansPortal HypertensionPortal PressurePortal Venous SystemPortal vein structurePreparationProdrugsProphylactic treatmentProteinsRattusRuptureSafetySerumSmall Business Innovation Research GrantSteatohepatitisSurvival RateTherapeuticToxic effectUnited States Food and Drug AdministrationVaricosityVascular resistanceVasopressinsanalogcommercializationcomparative efficacycopolymercostdrug candidatehemodynamicsimprovedin vivomortalitynanocarriernew technologypressurepreventpublic health relevanceresponsesuccesssynthetic peptidevasoactive agent
项目摘要
DESCRIPTION (provided by applicant): Portal hypertension (increased pressure in the portal venous system) is one of the main consequences of cirrhosis. Although the reduction of portal hypertension is well documented to prevent the development of life-threatening consequences, including bleeding esophageal varices and hepatorenal syndrome (HRS), pharmacological treatment options are severely limited. The synthetic peptide drug terlipressin has been used in Europe for the past twenty years as one of the safest, most cost-effective and economical drugs to reduce portal hypertension and treat bleeding varices and hepatorenal syndrome. However, its short half life necessitates its administration by IV 4-6x daily, limiting its application to the acute care setting. Our long term goal, in collaboration with our commercialization partner LAT-Pharma LLC, is to develop a long-acting formulation of terlipressin that can be ideally administered by sub-Q injection allowing for once daily administration for the management of portal-hypertension. The aims of the Phase I project are directed toward demonstrating that formulation of terlipressin with our proprietary nanocarrier affords an increase in half-life and a sustained release of the active agent with a prolonged pharmacological effect in vivo compatible with once-daily dosing. Terlipressin is currently not approved in the US and the envisioned drug candidate would have a significant market opportunity both in the acute care setting for life-threatening consequences of portal hypertension, and in the outpatient setting for the prophylactic treatment of portal hypertension.
PUBLIC HEALTH RELEVANCE: The envisioned drug candidate is expected to be the first agent available that will allow cirrhotic patients and their physicians reduce portal hypertension in the outpatient setting, thereby avoiding emergency treatment of life-threatening bleeding variceal ruptures and Hepatorenal syndrome.
描述(由申请人提供):门静脉高压(门静脉系统压力升高)是肝硬化的主要后果之一。虽然门静脉高压的降低被充分证明可以防止危及生命的后果的发展,包括出血性食管静脉曲张和肝肾综合征(HRS),但药物治疗选择非常有限。合成肽类药物特利加压素在过去的二十年里一直在欧洲使用,作为最安全,最具成本效益和经济的药物之一,以降低门静脉高压症和治疗出血静脉曲张和肝肾综合征。然而,其短半衰期需要每天IV 4- 6次给药,限制了其在急性护理环境中的应用。我们的长期目标是与我们的商业化合作伙伴LAT-Pharma LLC合作,开发一种长效特利加压素制剂,该制剂可以理想地通过sub-Q注射给药,允许每天给药一次,用于门脉高压的管理。I期项目的目的是证明特利加压素与我们专有的纳米载体的制剂提供了半衰期的增加和活性剂的持续释放,具有与每日一次给药相容的体内延长的药理学作用。特利加压素目前尚未在美国获得批准,预期的候选药物将在门静脉高压危及生命后果的急性护理环境和门静脉高压预防性治疗的门诊环境中具有重要的市场机会。
公共卫生相关性:预期的候选药物有望成为第一个可用的药物,将允许门静脉高压症患者及其医生在门诊环境中降低门静脉高压症,从而避免危及生命的静脉曲张破裂出血和肝肾综合征的紧急治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elijah M. Bolotin其他文献
Compositions de supports a noyau hydrophobe pour l'administration d'agents therapeutiques, et procedes de preparation et d'utilisation
支持治疗剂施用、制备和利用过程的疏水性组合物
- DOI:
- 发表时间:
2006 - 期刊:
- 影响因子:0
- 作者:
Gerardo M. Castillo;Elijah M. Bolotin - 通讯作者:
Elijah M. Bolotin
Erratum to: Protected Graft Copolymer Excipient Leads to a Higher Acute Maximum Tolerated Dose and Extends Residence Time of Vasoactive Intestinal Peptide Significantly Better than Sterically Stabilized Micelles
- DOI:
10.1007/s11095-013-1061-0 - 发表时间:
2013-05-09 - 期刊:
- 影响因子:4.300
- 作者:
Sandra Reichstetter;Gerardo M. Castillo;Israel Rubinstein;Akiko Nishimoto-Ashfield;ManShun Lai;Cynthia C. Jones;Aryamitra Banerjee;Alex Lyubimov;Duane C. Bloedow;Alexei Bogdanov;Elijah M. Bolotin - 通讯作者:
Elijah M. Bolotin
Elijah M. Bolotin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elijah M. Bolotin', 18)}}的其他基金
Vasoactive Intestinal Peptide for the treatment of Female Sexual Arousal Disorder
血管活性肠肽治疗女性性唤起障碍
- 批准号:
8638840 - 财政年份:2014
- 资助金额:
$ 22.34万 - 项目类别:
Nanocarrier formulated enzyme for the treatment of S. aureus infection
纳米载体配制的酶用于治疗金黄色葡萄球菌感染
- 批准号:
8468113 - 财政年份:2012
- 资助金额:
$ 22.34万 - 项目类别:
Vasoactive intestinal peptide for the treatment of psoriasis
血管活性肠肽治疗牛皮癣
- 批准号:
8248548 - 财政年份:2012
- 资助金额:
$ 22.34万 - 项目类别:
Nanocarrier formulated enzyme for the treatment of S. aureus infection
纳米载体配制的酶用于治疗金黄色葡萄球菌感染
- 批准号:
8392195 - 财政年份:2012
- 资助金额:
$ 22.34万 - 项目类别:
Vasoactive intestinal peptide for the treatment of psoriasis
血管活性肠肽治疗牛皮癣
- 批准号:
8540904 - 财政年份:2012
- 资助金额:
$ 22.34万 - 项目类别:
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR
纳米载体配制的抗纤维化肽治疗肝硬化 - Fast Track SBIR
- 批准号:
8102077 - 财政年份:2010
- 资助金额:
$ 22.34万 - 项目类别:
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR
纳米载体配制的抗纤维化肽治疗肝硬化 - Fast Track SBIR
- 批准号:
8097148 - 财政年份:2010
- 资助金额:
$ 22.34万 - 项目类别:
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR
纳米载体配制的抗纤维化肽治疗肝硬化 - Fast Track SBIR
- 批准号:
7901175 - 财政年份:2010
- 资助金额:
$ 22.34万 - 项目类别:
Nanocarrier with metal bridge for affinity based delivery of metal binding peptid
具有金属桥的纳米载体,用于基于亲和力的金属结合肽的递送
- 批准号:
7568232 - 财政年份:2008
- 资助金额:
$ 22.34万 - 项目类别:
Nanocarrier with metal bridge for affinity based delivery of metal binding peptid
具有金属桥的纳米载体,用于基于亲和力的金属结合肽的递送
- 批准号:
7475033 - 财政年份:2008
- 资助金额:
$ 22.34万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.34万 - 项目类别:
Research Grant